Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome
Grzegorz Helbig(Medical University of Silesia), Sławomira Kyrcz‐Krzemień(Medical University of Silesia), Magdalena Hałasz(University of Rzeszów), Marek Dudziński(Rzeszów University), Małgorzata Stachowicz(Medical University of Silesia), Agnieszka Więcławek(Medical University of Silesia), Marek Hus(Medical University of Lublin), Anna Soja(Medical University of Silesia)
Cited by 28
Related Papers
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2024|162
Therapy‐related peripheral neuropathy in multiple myeloma patients
|Hematological Oncology|2014|70